Joint Formulary & PAD

Fluticasone with salmeterol (Seretide Accuhaler) - Chronic Obstructive Pulmonary Disease (COPD)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Inhaler (dry powder)
Associated Icons :
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Fluticasone with salmeterol (Seretide Accuhaler)
Indication :
Chronic Obstructive Pulmonary Disease (COPD)
Group Name :
Keywords :
ICS/LABA, Inhaled Corticosteroids
Brand Names Include :
Seretide Accuhaler
Important Information :

Not for initiation in new patients.

Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
5

Other Indications

Below are listed other indications that Fluticasone with salmeterol (Seretide Accuhaler) is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Chronic Obstructive Pulmonary Disease (COPD).

Committee Recommendations (2)

Seretide Accuhaler (and other fluticasone containing ICS/LABAs) is NOT a locally preferred device although there is no expectation for existing stable patients to change drug or device unless agreed as a clinically appropriate course of action.

The locally preferred ICS/LABA devices are as follows:

Low carbon:

  • Fostair Nexthaler (beclometasone / formoterol DPI)
  • Fobumix Easyhaler (budesonide / formoterol DPI)
  • Relvar Ellipta (Fluticasone / vilanterol DPI)
  • Symbicort Turbohaler (budesonide / formoterol DPI)

Alternative devices:

  • Fostair (beclometasone / formoterol MDI)
  • Symbicort (budesonide / formoterol MDI)

Devices should be prescribed by BRAND

A spacer device should be used with MDI devices.

See full COPD guidelines below

The PCN endorsed the use of the ICS steriod Card. Implementation of its use should be left to the discretion of individual CCGs